Pipeline news

• Syndax Announces Updated Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA® (pembrolizumab) in Non-Small Cell Lung Cancer

  24 September 2018

  

  Syndax Pharmaceuticals, Inc.  ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced updated results from the ongoing ENCORE 601 cohort enrolling non-small cell lung cancer (NSCLC) patients previously treated with both chemotherapy and PD-(L)1 therapy. 

• Epic Sciences Announces Publication Showing Blood Test Could Help Select Metastatic Prostate Cancer Patients Who Respond to PSMA-Targeted Therapies

  24 September 2018

  

  Epic Sciences, in partnership with Memorial Sloan Kettering (MSK), have demonstrated that a liquid biopsy blood test may be used in clinical trials to find patients who are likely to benefit from PSMA-targeted therapies, before treatment is initiated. The blood test, developed by Epic Sciences, looks on the surface of circulating tumor cells (CTCs) for a specific protein, called prostate-specific membrane antigen (PSMA), that is highly expressed in prostate cancer. In the study, the presence of PSMA-positive CTCs in patients with metastatic prostate cancer was related to the patient’s therapeutic response and clinical outcomes to an antibody drug conjugate (ADC) therapy targeting PSMA-positive prostate cancer cells.

• Positive PEACHTREE Data to be Highlighted at EURETINA 2018

  18 September 2018

  

  Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that data from PEACHTREE, its pivotal Phase 3 trial of suprachoroidal CLS-TA in patients with macular edema associated with non-infectious uveitis, will be presented by  Ron Neumann , MD, Uveitis Specialist at  Maccabi Health Services ,  Tel Aviv, Israel  and co-Chair of the International Symposium of Ocular Pharmacology and Therapeutics, during a Uveitis Free Paper session at the upcoming  European Society of Retina Specialists (EURETINA) Congress  2018 in  Vienna, Austria.

• Data From Clearside Biomedical’s Pivotal Phase 3 PEACHTREE Clinical Trial in Macular Edema Associated with Non-Infectious Uveitis to be Presented at the Retina Society 51st Annual Scientific Meeting

  13 September 2018

  

  Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that data from PEACHTREE, its pivotal Phase 3 trial of suprachoroidal CLS-TA in patients with macular edema associated with non-infectious uveitis, will be presented by  Rahul N. Khurana , MD, an investigator for PEACHTREE, Partner at  Northern California Retina Vitreous Associates , and Clinical Associate Professor in Ophthalmology at  UCSF Medical Center , during a scientific session on Inflammation at the  Retina Society  51st Annual Scientific Meeting in  San Francisco , California. 

• Epic Sciences Announces Completion of $52 Million Series E Financing

  12 September 2018

  

  Epic Sciences (Epic) announced today that the company has completed a $52 million Series E financing led by Blue Ox Healthcare Partners, with participation by Deerfield Management and Varian (NYSE: VAR). Existing investors, including Altos Capital Partners, Genomic Health, Inc., Domain Associates, VI Ventures, Alexandria Venture Investments, and Sabby Management, also participated in the financing.  

• Clearside Biomedical Appoints Viral Kansara as Vice President, Discovery

  12 September 2018

  

  Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, today announced the appointment of Viral Kansara, Ph.D. to the position of Vice President, Discovery. 

• Clearside Biomedical Appoints Accomplished Pharmaceutical Industry Legal Executive, Leslie Zacks, as General Counsel and Chief Compliance Officer

  11 September 2018

  

  Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, today announced the appointment of  Leslie Zacks  as General Counsel and Chief Compliance Officer.

• Researchers provide compelling evidence for multiple STI-detecting device

  11 September 2018 St. George's University of London / Medical Xpress

  

  Using mathematical modelling, researchers within the Applied Diagnostics Research and Evaluation Unit at the university concluded that a bespoke point-of care diagnostic device could significantly reduce the number of return clinical visits and the average time-to-cure from about a week to one day. The device is in early phases of development by Atlas Genetics Limited, following a grant from from Innovate UK via the Small Business Research Initiative.

• Clearside Biomedical Further Strengthens Commercial Organization With Appointment of Lester Rodríguez as Vice President, Quality

  06 September 2018

  

  Clearside Biomedical, Inc. (NASDAQ: CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, today announced the appointment of Lester Rodríguez as Vice President, Quality.

• Marinus Appoints Scott Braunstein, MD to its Board of Directors

  05 September 2018

  

  Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced the appointment of Dr.  Scott Braunstein  to its Board of Directors. Dr. Braunstein brings over 20 years of knowledge and experience from diverse biotechnology and pharmaceutical industry vantage points.